Press Releases

Dyax Corp. to Present at the Rodman & Renshaw Annual Global Investment Conference


CAMBRIDGE, Mass., May 10, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Rodman & Renshaw 6th Annual Global Investment Conference, being held May 16-18th at the Grosvenor House Hotel in London, UK. Mr. Christensen will present a corporate progress report, including an update on the Company's commercial activities for KALBITOR(R) (ecallantide) and clinical development programs. The Dyax presentation is scheduled for Tuesday, May 18th at 9:25 AM (GMT).

The Dyax presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at The 35-minute presentation will also be available on the Dyax website for a limited period of time following the conference.

About Dyax Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs.

Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Our lead product, DX-88, has been approved under the brand name KALBITOR(R) (ecallantide) in the United States for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.

In addition to its approved commercial use, DX-88 is also being evaluated for its therapeutic potential in other angioedema indications (acquired and ACE inhibitor-induced angioedemas) and, through a collaboration with Fovea Pharmaceuticals (a subsidiary of sanofi aventis), is in a Phase 1 trial for retinal vein occlusion-induced macular edema.

DX-88 and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit

SOURCE: Dyax Corp.

CONTACT: Dyax Corp. Nicole Jones, 617-250-5744 Director, Investor Relations and Corporate Communications Copyright Business Wire 2010 -0- KEYWORD: United Kingdom

United States


North America

Massachusetts INDUSTRY KEYWORD: Health


Clinical Trials




Other Health

Professional Services

Finance SUBJECT CODE: Conference

Trade Show